Document is current

Article History

Received: 15 August 2023

Accepted: 20 October 2023

First Online: 20 November 2023

Declarations

:

: B.S. reports speaker fees from Abiomed, Abbott and AstraZeneca, outside of the submitted work. L.F.B. reports speaker fees from Abiomed, outside of the submitted work. S.B. reports grants and personal fees from Abbott Diagnostics, Bayer, Siemens, Thermo Fisher, grants from Singulex, personal fees from Abbott, AstraZeneca, Amgen, Medtronic, Pfizer, Roche, Siemens Diagnostics, Novartis, outside of the submitted work. J.D. received speaker fees from Astra-Zeneca, Boehringer-Ingelheim and Bayer. D.E. reports speaker fees from Abiomed, Biotronik and Daiichi sankyo, outside of the submitted work. P.K. was partially supported by European Union AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (PG/17/30/32961; PG/20/22/35093; AA/18/2/34218), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), Deutsche Forschungsgemeinschaft (Ki 509167694), and Leducq Foundation; receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last three years; is listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). S.K. received research support from Cytosorbents and Daiichi Sankyo. He also received lecture fees from ADVITOS, Biotest, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Shionogi and Zoll. He received consultant fees from Fresenius, Gilead, MSD and Pfizer. P.L. received speaker honoraria and consulting fees from Astra Zeneca, Bayer, Pfizer, Edwards Lifesciences, and research honoraria from Edwards Lifesciences, outside of the submitted work. S.M.-W. reports Abiomed unrestricted grant for JenaMacs trial. Speakers honoraria: Abiomed, Boston Scientific, Pfizer, Daichi Sankyo, outside of the submitted work. M.O. reports speaker honoraria and travel compensations from companies Abbott Medical, AstraZeneca, Abiomed, Bayer vital, BIOTRONIK, Bristol-Myers Squibb, CytoSorbents, Daiichi Sankyo Deutschland, Edwards Lifesciences Services, Sedana Medical. F.P. consultant for Abiomed. T.R. received speaker honoraria and consulting fees from Astra Zeneca, Bayer, Pfizer, Daiichi Sankyo. None of them was related to this study. C.S. reports speaker honoraria from AstraZeneca, outside the submitted work. P.C.S. received honoraria for lectures/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, BMS, Abiomed, Pharmacosmos and Amgen not related to this article; and research support for the department from Boehringer Ingelheim, Edwards and Abiomed not related to this article. D.W. reports speaker fees from Abiomed, AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Novartis and Medtronic, outside of the submitted work. E.B.W. received speaker honoraria and consulting fees from Amarin, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, CVRx, Daiichi Sankyo, and Novartis, and a research grant from Boehringer-Ingelheim of outside the submitted work. All other authors did not declare a conflict of interest.